Pfizer's $130B Weight-Loss Dream Just Collapsed
2025-04-14 15:18
https://finance.yahoo.com/news/pfizers-130b-weight-loss-dream-151831937.html?.tsrc=rss
Oops, something went wrongTip: Try a valid symbol or a specific company name for relevant resultsOops, something went wrongTrump says he's 'looking at something' to help car companies with tariffsStocks rally for second straight day, while Apple jumps on tech tariff reprieveThe Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon tradingAmericans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey foundStocks surge as Apple leads way higher after tech's tariff reprieveTrump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bendGoldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slowsCorporate earnings take center stage amid tariff turmoil: What to know this weekTrump has tariffs, taxes, and the debt ceiling on a collision course for this summerTrump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)Tax day 2025 is coming up. Here’s what to know to file by the deadline.Commentary: Put the P/E ratio in timeout for nowMarket chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landingApple was on brink of crisis before tariff concession from Trump (Bloomberg)Corporate earnings take center stage amid tariff turmoil: What to know this weekThe best (and worst) time of year to buy a houseThe Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)How to invest in gold in 4 stepsChanging jobs can disrupt saving for retirement. Here's how to stay on track.Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard ofThe tariff uncertainty isn't getting any better in markets: Chart of the Week'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflationGold notches best week since 2020 amid 'shaken' investor confidence in USThe bond market just had one of its most volatile and unusual weeks in recent memoryStocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.Consumer sentiment craters further as inflation expectations soar to highest since 1981Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll inJPMorgan's Dimon says economy is facing 'considerable turbulence'Tariff uncertainty muddies — and refocuses — earnings seasonChina raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hikeChina already knows Trump's breaking point in their burgeoning trade war, our columnist writesHow the bond market helped make Trump blink on tariffsThe Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-offTrump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reportedStocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%.The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again.Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality checkInflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years.The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates.The 'Trump put' makes an appearanceMarch's report could be last time investors see inflation easing. Here's what to expect.Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today.Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008.Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid'The Nasdaq was up 10%, aiming for its biggest gain since 2008, after Trump paused some tariffs. The Dow soared 2,500 points.Trump unilaterally raises tariff rate on China to 125%, pauses 'reciprocal' tariffs on other countriesThe major indexes rocketed higher after Trump announced a '90-day pause on tariffs for most countries.Unlock stock picks and a broker-level newsfeed that powers Wall Street.Pfizer (NYSE:PFE) just pulled the plug on its daily weight-loss pill, danuglipron, after a clinical trial flagged a potential drug-related liver injury. That decision comes after earlier setbacks tied to severe nausea in its twice-daily versionand leaves Pfizer even further behind in a weight-loss market expected to hit $130 billion by 2030. With demand for Covid products fading fast, the company had pinned big hopes on obesity drugs to fill the gap. Instead, it's now heading back to the drawing board.Warning! GuruFocus has detected 6 Warning Signs with PFE.The market didn't take the news lightly. Pfizer shares dropped around 1% premarket 8.59am, while rivals popped. Novo Nordisk (NYSE:NVO) jumped 2.75%, Eli Lilly (NYSE:LLY) rose 2.27% , and Viking Therapeutics (NASDAQ:VKTX) soared nearly 20% in the premarket trading at the same timeall riding momentum from stronger weight-loss offerings. Lilly's Zepbound, a once-weekly injectable, is already generating nearly $5 billion a year and has an oral version in the final stretch of trials. Structure Therapeutics and AstraZeneca aren't far behind, with their own oral contenders in the pipeline.This misstep throws more heat on Pfizer CEO Albert Bourla, who's under pressure to offset looming patent cliffs that could wipe out $15 billion in revenue by decade's end. So far, the pipeline hasn't delivered, and the M&A spree hasn't produced a clear winner. As competitors rack up approvals and market share, Pfizer may have to rethink its next moveand fast. Investors will be watching closely to see if another round of strategic acquisitions is in the cards.This article first appeared on GuruFocus.Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks on Jim Cramer’s radar. On Thursday, Mad Money host Jim Cramer cautioned viewers about what may lie ahead once the 90-day pause on new […]Pfizer bows, but is not entirely out of the GLP-1 race.The Dow Jones rose on the stock market today and auto stocks popped after President Donald Trump spoke out. Palantir stock was higher while Nvidia fell.How much does the radio host expect you to invest each year?Retiring on a fixed income can seem daunting, but with some planning and commitment to a frugal lifestyle, it's possible to retire comfortably on $2,000 a month. This takes discipline but ultimately...Many people see financial prosperity as an unattainable dream reserved only for those born into affluent families or lucky and talented enough to attain fantastic six-figure jobs. In a YouTube video,...United Wholesale Mortgage claims the top spot on the latest list.It is very rare for an ordinary household to owe money on gifts. The gift tax has a somewhat complicated two-tier structure. Each year you can give up to an annual amount (the "annual exclusion") without paying, or even reporting, anything on your taxes. Then, over your lifetime, you have a significantly higher amount that […] The post I Want to Give $65k to My Daughter and Her Husband. Will We Have to Pay Taxes? appeared first on SmartReads by SmartAsset.Tip: Try a valid symbol or a specific company name for relevant resultsSign in to access your portfolio


Try again.
